Chiesi to acquire KalVista for $1.9 billion in rare disease expansion
Tweet Send to a Friend
Chiesi Group announced it will acquire KalVista Pharmaceuticals Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing approximately $1.9 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
